Porter &amp; Company Trump wipes out trillions overnight… Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&amp;P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move. Whether you take some of that wealth for yourself depends on if you watch this controversial exposé\n\nHinge Health Inc. ( - ) - Investment analysts at KeyCorp issued their Q2 2025 earnings estimates for shares of Hinge Health in a report released on Monday, June 16th. KeyCorp analyst S. Schoenhaus expects that the company will post earnings of $0.09 per share for the quarter. KeyCorp has a \"Overweight\" rating and a $45.00 price objective on the stock. KeyCorp also issued estimates for Hinge Health's Q3 2025 earnings at $0.09 EPS, Q4 2025 earnings at $0.15 EPS, FY2025 earnings at $0.55 EPS, Q1 2026 earnings at $0.08 EPS, Q2 2026 earnings at $0.13 EPS, Q3 2026 earnings at $0.21 EPS, Q4 2026 earnings at $0.33 EPS, FY2026 earnings at $0.76 EPS, Q1 2027 earnings at $0.25 EPS and FY2027 earnings at $1.17 EPS.\n\nOther equities research analysts also recently issued research reports about the company. raised Hinge Health to a \"hold\" rating in a research report on Monday, June 2nd. Needham &amp; Company LLC initiated coverage on Hinge Health in a research report on Monday. They set a \"buy\" rating and a $47.00 target price for the company. Barclays began coverage on Hinge Health in a research report on Monday. They issued an \"overweight\" rating and a $43.00 price target on the stock. William Blair initiated coverage on Hinge Health in a research note on Monday. They issued an \"outperform\" rating for the company. Finally, Canaccord Genuity Group assumed coverage on shares of Hinge Health in a research note on Monday. They set a \"buy\" rating and a $52.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of \"Moderate Buy\" and a consensus target price of $46.00.\n\nHinge Health Stock Up 4.7% Shares of traded up $1.79 during mid-day trading on Wednesday, hitting $39.79. 771,425 shares of the company's stock were exchanged, compared to its average volume of 815,806. Hinge Health has a 52 week low of $33.42 and a 52 week high of $43.80.\n\nAbout Hinge Health () Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.

KeyCorp Forecasts Hinge Health's Q2 Earnings (NYSE:HNGE)

KeyCorp released Q2 2025 earnings estimates for Hinge Health, projecting $0.09 per share with an "Overweight" rating and $45.00 price target. Other analysts, including Needham & Company, Barclays, William Blair, and Canaccord Genuity Group, also issued ratings and price targets. Hinge Health's stock rose 4.7% to $39.79, with 771,425 shares traded. The company describes itself as leveraging AI-driven software to transform healthcare outcomes.